Orphazyme AS (CHIX:ORPHAC) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Orphazyme AS's annualized Gross Profit for the quarter that ended in Jun. 2022 was kr0.00 Mil. Orphazyme AS's average Total Assets over the quarter that ended in Jun. 2022 was kr133.41 Mil. Therefore, Orphazyme AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 was 0.00%.

Orphazyme AS Gross-Profit-to-Asset % Historical Data

The historical data trend for Orphazyme AS's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Gross-Profit-to-Asset % Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

7.27

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									-	-	-	48.16	-

Competitive Comparison of Orphazyme AS's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Orphazyme AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Gross-Profit-to-Asset % falls into.

Orphazyme AS Gross-Profit-to-Asset % Calculation

Orphazyme AS's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
	=	36.193	/	( (822.493	+	173.229)	/ 2 )
	=	36.193	/	497.861
	=	7.27 %

Orphazyme AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2022 )	/	( (Total Assets (Q: Dec. 2021 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
	=	0	/	( (173.229	+	93.589)	/ 2 )
	=	0	/	133.409
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Orphazyme AS Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines